UPDATE: 3SBio Enters 'Go Private' Deal, Consideration Raised to $2.3857/Share or $16.70/ADS

3SBio Inc. (NASDAQ: SSRX ) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has entered into an amendment (the "Amendment") to its previously announced agreement and plan of merger dated as of February 8, 2013, by and among Decade